SCHEMBL288283

SCHEMBL288283

CS(=O)(=O)c1ccc2c(c1)CCN2c1cc(OC2CCN(C(=O)O)CC2F)ncn1

nearest known ligand 0.64

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 19/20 0.64
ROCK1 Q13464 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17091631 1.00 GPR119 (0.64) GPR119ROCK1
SCHEMBL17091632 1.00 GPR119 (0.64) GPR119ROCK1
SCHEMBL3233358 0.90 GPR119 (0.66) GPR119
SCHEMBL3233374 0.90 GPR119 (0.66) GPR119
SCHEMBL3241667 0.90 GPR119 (0.78) GPR119
SCHEMBL3233365 0.90 GPR119 (0.66) GPR119
SCHEMBL3241662 0.90 GPR119 (0.78) GPR119
SCHEMBL3241658 0.90 GPR119 (0.78) GPR119
SCHEMBL299959 0.86 GPR119 (0.80) GPR119
SCHEMBL2717368 0.85 GPR119 (0.72) GPR119ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2210886-B1 PYRIMIDYL INDOLINE COMPOUND DAIICHI SANKYO CO LTD (JP) 2015-09-23 EP claimed
EP-2427450-A1 GPR 119 MODULATORS Pfizer Inc. (US) 2012-03-14 EP disclosed
EP-2427448-A1 Gpr 119 modulators Pfizer Inc. (US) 2012-03-14 EP disclosed
US-20120052130-A1 GPR 119 MODULATORS PFIZER INC. 2012-03-01 US disclosed
WO-2010128414-A1 GPR 119 MODULATORS PFIZER INC. (US) 2010-11-11 WO disclosed
WO-2010128425-A1 GPR 119 MODULATORS PFIZER INC. (US) 2010-11-11 WO disclosed
US-20100285145-A1 GPR 119 MODULATORS PFIZER INC 2010-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120052130-A1 GPR 119 MODULATORS GPR119, GPR39, GPR65 GPR119 1/4885ROCK1 2922/4885
US-20100285145-A1 GPR 119 MODULATORS GPR119, GPR65, GPR39 GPR119 1/4885ROCK1 2613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.